Stefanie Gollner

Ernst Grube Street 40
Halle, NI 06120, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Journal: Nature medicine
Published: January 07, 2026

The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance.

The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance.

Journal: Leukemia
Published: December 06, 2023

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations.

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations.

Journal: Leukemia
Published: May 05, 2023

The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia.

The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia.

Journal: Leukemia
Published: November 05, 2022

AKTing on XPO1 inhibition in AML.

AKTing on XPO1 inhibition in AML.

Journal: Nature cancer
Published: July 26, 2022

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.

Journal: Leukemia
Published: May 23, 2022

A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia.

A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia.

Journal: Cancer discovery
Published: February 21, 2022

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.

Journal: Blood
Published: September 27, 2021

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia.

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia.

Journal: Scientific reports
Published: June 22, 2021

Epitranscriptomic modifications in acute myeloid leukemia: m6A and 2'-O-methylation as targets for novel therapeutic strategies.

Epitranscriptomic modifications in acute myeloid leukemia: m6A and 2'-O-methylation as targets for novel therapeutic strategies.

Journal: Biological chemistry
Published: June 08, 2021

CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.

CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.

Journal: International journal of cancer
Published: March 01, 2021

Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response.

Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response.

Journal: Nature cancer
Published: November 20, 2020
Showing 1-12 of 29

Last Updated: 09/26/2026